PENRITH, UNITED KINGDOM — Plasvacc UK Ltd. is pleased to announce its entry into the United Kingdom through its acquisition of Veterinary Immunogenics Inc.
Effective immediately, Plasvacc will undertake the day-to-day management of Veterinary Immunogenics under the oversight of site manager Fergus Macarthur.
Incorporated in 1992, Veterinary Immunogenics has been producing and supplying hyperimmunised equine plasma products for veterinary use for over 30 years under the Hypermune and Hypermune RE brand names. With an emphasis on customer care, Veterinary Immunogenics has specialised in providing high-quality plasma products to veterinarians, breeders and trainers in the UK, Ireland & European countries.
“With an impressive track record spanning three decades, we’re grateful for the tireless efforts of Dr. Thomas Barr BVMS MRCVS and Eileen Barr to advance plasma-based equine veterinary medicine in the United Kingdom,” said Andrew Macarthur, CEO of Plasvacc UK Ltd.
“A sure sign that Veterinary Immunogenics was a great fit for the Plasvacc Group of Companies was their unwavering commitment to product quality and exceptional customer service that closely mirrors our own. We’re very pleased to be adding the first-rate Veterinary Immunogenics employees to the Plasvacc Team,” continued Macarthur.
Aside from the transition in management, the Veterinary Immunogenics product line and day-to-day operations will remain unchanged.
About Plasvacc’s International Companies
Founded in 1996 as Plasvacc Pty. Ltd. in Australia and expanded through Plasvacc USA Inc. in 2005, Plasvacc’s global companies manufacture and distribute high-quality hyperimmunised blood plasma products used to supplement the immune response system in animals. Firmly committed to animal ethics, Plasvacc prides itself in delivering the highest quality product possible while delivering unmatched customer service and technical support.
